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We examined the effect of oral administration of
juzen-taiho-to, one of the most popular herbal medi-
cines in Japan, on primary melanocytic tumor
growth in RET-transgenic mice. There was virtually
no difference between the lengths of tumor-free
stages in the juzen-taiho-to-treated mice and the
untreated littermate control mice. The rate of tumor
growth in the juzen-taiho-to-treated mice, however,
was greatly suppressed during the entire period after
the initial tumor development. Correspondingly, the
life span of juzen-taiho-to-treated transgenic mice was
longer (over 6 mo in mean value) than that of con-
trol mice. We partially elucidated the mechanism of
the antitumor effect of juzen-taiho-to. The addition of
juzen-taiho-to at any of a wide range (50±1600 mg per
ml) of concentrations to in vitro cultures of Mel-Ret
cells, a malignant melanoma cell line derived from a
RET-transgenic mouse, caused neither cell death nor
cell cycle arrest directly. The addition of 50±400 mg
per ml of juzen-taiho-to to cultures of murine spleen
cells, however, promoted their DNA synthesis. More
importantly, peritoneal exudate cells from the juzen-
taiho-to-treated transgenic mice, in which the ratio
and number of T cells were increased, displayed an
antitumor immunity against Mel-Ret cells in vitro.
Interestingly, the peritoneal-exudate-cell-associated
antitumor immunity was further augmented by the
addition of 200±400 mg per ml of juzen-taiho-to
in vitro. This immunity, which was primarily con-
veyed by Thy-1+ T cells, was antigen (RET/mela-
noma) speci®c and cytotoxic. Amongst various
chemical ingredients of juzen-taiho-to examined in
this study, glycirrhizin displayed an action, partially
replacing that of juzen-taiho-to, in promoting anti-
Mel-Ret immunity when supplementarily added
in vitro. These results suggest that juzen-taiho-to sup-
presses once-developed primary melanocytic tumors
through potentiation of T-cell-mediated antitumor
cytotoxic immunity in vivo. Key words: antitumor
immunity/glycirrhizin/malignant melanoma. J Invest
Dermatol 117:694±701, 2001
M
alignant melanoma is one of the most aggressive
human cancers, and the incidence of skin
malignant melanoma in the world is increasing
at a greater rate than that of any other human
cancer (Gleason et al, 1993; Chen et al, 1996).
Elucidation of the pathogenesis and establishment of an effective
protocol for prevention and therapy of malignant melanoma are
therefore needed urgently. We previously established an oncogene
RET-transgenic mouse line, line 304/B6, in which skin melanosis,
benign melanocytic tumor, and malignant melanoma develop
stepwise (Kato et al, 1998b). A cell line of malignant melanoma,
Mel-Ret, was also established from a RET-transgenic mouse
(Taniguchi et al, 1992). In this animal model, we previously
showed that the RET oncogene product or RET-induced tumor-
speci®c antigen(s) can be the major target of antitumor T cell
immunity (Ichihara et al, 1995; Kato et al, 1999). This antitumor T
cell immunity developed in line 304 of RET-transgenic mice by
repeated inoculation of alloantigen/RET-bearing melanocytic
tumors for partial tumor growth suppression (Ichihara et al, 1995)
and spontaneously in line 242 of RET-transgenic mice that are
defective of immunologic tolerance to the RET antigen for
complete growth inhibition (Kato et al, 1999). Another approach
for the development of effective preventive/therapeutic protocols
against tumor development in this model was the use of a herbal
medicine, sho-saiko-to (SST), which has been widely used in clinics
in Japan for treatment of chronic hepatitis and liver cirrhosis (Kato
et al, 1998a). Oral administration of SST signi®cantly prolonged the
tumor-free stage in transgenic mice of line 304/B6 and suppressed
the growth of once-developed tumors at the early stage of tumor
development, although it barely suppressed the growth of fully
developed tumors at the late stage. SST displayed direct
cytotoxicity against tumor cells in vitro, and this activity seemed
to be primarily involved in the mechanism of SST-mediated tumor
growth suppression (Kato et al, 1998a). Corresponding to this
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result, SST induced apoptosis of tumor cells, at least in part,
through the promotion of expression of cell surface Fas and Fas-
ligand and caused cell cycle arrest by regulating cyclin-dependent
kinase activities (Liu et al, 1998). Baicalin and glycirrhizin, two of
the many ingredients of SST, were shown to be mainly responsible
for the ®rst (Kato et al, 1998a) and second (Liu et al, 1998) activities
of SST, respectively. Saikosaponin-d and ginsenoside Rb1, two
other ingredients of SST, as well as glycirrhizin, have also been
previously shown to display distinct actions for promoting the
ligand (anti-CD3 or concanavalin A, Con A) stimulated T cell
growth response (Zhang et al, 1992, 1993, 1995; Kato et al, 1994,
1995), H-2 class I antigen on lymphocytes (Zhang et al, 1990), and
NO production by macrophages (Fan et al, 1995; Yi et al, 1996).
Juzen-taiho-to (JTT), another well-known herbal medicine, has
also been used widely in clinics in Japan for normalization of
impaired immune activity and general cellular function in chron-
ically diseased patients, including patients with malignant tumors
for expectation of a recovery from anticancer-therapy-induced
leukopenia and a potential increase in antitumor immunity
(Ohnishi et al, 1990, 1996). Potential bene®ts of JTT for such
patients have been indicated by experimental results demonstrating
the actions of JTT in protection of mice from anticancer drugs or
radiation toxicities (Haranaka et al, 1985; Sugiyama et al, 1995a, b),
in increasing mitogen-induced growth and antibody responses of
splenic lymphocytes (Hamada et al, 1988; Kiyohara et al, 1991), in
promotion of the production of a number of cytokines such as
interleukin-2 (IL-2), IL-4, IL-5, IL-6, G-CSF, granulocyte
macrophage colony stimulating factor, tumor necrosis factor a,
interferon g (Kiyohara et al, 1993; Iijima et al, 1999; Matsumoto and
Yamada, 2000; Matsumoto et al, 2000), and in inhibition of the
growth (Haranaka et al, 1985; Maruyama et al, 1993; Zhang et al,
1995; Ohnishi et al, 1996) and metastasis (Ohnishi et al, 1996) of
transplanted tumors in mice, possibly through activation of
macrophages/T cells (Maruyama et al, 1993; Zhang et al, 1995)
and natural killer T cells (Ohnishi et al, 1996; Matsumoto et al,
2000). Despite the use of JTT for cancer patients in Japan, it still
remains unclear whether JTT, possibly through its immunity-
modifying effects, actually inhibits the growth of primarily
developed tumors that less easily induce tumor-rejecting T cell
immunity than transplanted tumors. In this study, we investigated
the effect of oral administration of JTT on the growth of
melanocytic tumors that had primarily developed in RET-
transgenic mice. We demonstrated, for the ®rst time, that JTT
does in fact suppress the growth of primarily developed
melanocytic tumors in RET-transgenic mice, not by prolonging
the tumor-free stage after birth but by suppressing tumor growth
during the entire period after initial tumor development. Unlike
the previously reported antitumor activity of SST, JTT was found
to suppress tumor growth primarily through promoting antitumor
cytotoxic T cell immunity.
MATERIALS AND METHODS
Reagents JTT and SST, the quality of which had been controlled by
Japanese Pharmacopeia, were obtained from Tsumura, Tokyo, Japan.
Mixtures of 10 kinds of herbs (Ginseng Radix, Glycyrrhizae Radix,
Polygalae Radix, Cinnamomi Cortex, Rehmanniae Radix, Paeoniae Radix,
Cnidii Rhizoma, Atractylodis Lanceae Rhizoma, Angelicae Radix, Hoelen) for
JTT and of six kinds of herbs (Bupleuri Radix, Pinelliae Tuber, Sctellariae
Radix, Zizyphi Fructus, Zingiberis Rhizoma, Ginseng Radix, Glycyrrhizae
Radix) for SST were added with water and extracted at 100°C ovcr a
period of 1 h (Ohnishi et al, 1990). The extracted solution was ®ltered
and dried to obtain the extract powder. The blended powder was
dissolved in distilled water for oral administration to mice or dissolved in
tissue culture medium for in vitro use (see below). Some puri®ed
ingredients of JTT, such as paeoni¯orin, liquiritin, glycyrrhizin, and
ginsenoside Rbl (Saiki et al, 1999) were purchased from Wako, Osaka,
Japan.
JTT treatment of RET-transgenic mice RET-transgenic mice of
line 304/B6 (Kato et al, 1998b), which were established by crossing RET-
transgenic mice of line 304 (originating from a BCF1 mouse; H-2b/d)
several times with C57BL/6 (H-2b) mice, were randomly divided into
two groups after birth. One group (experimental group) was given
drinking water containing 3±5 mg per d per mouse of JTT, which
corresponds to the usual human dosage in conversion per weight, from 1
mo of age until death. The other group (control group) was given plain
drinking water only. Each of the two groups consisted of several divided
litters. For analysis of tumor volume and life span, 35 transgenic mice
were used for each group. This study was approved by the Animal Care
and Use Committee of Nagoya University School of Medicine.
Cell line and culture Mel-Ret cells, which were previously
established as a melanoma cell line from a tumor developed in a RET-
transgenic mouse of line 304, were suspended in RPMI-1640 medium
supplemented with 10% fetal bovine serum and 100 U penicillin per ml,
100 mg streptomycin per ml, 2 mM L-glutamine, and 50 mM 2-
mercaptoethanol (complete medium) in 60 3 15 mm tissue culture
dishes (Coning, NY). JTT was dissolved in the complete medium to a
concentration of 10 mg per ml. This stock solution was passed through
0.22 mm ®lters for sterilization. In this study, we also used a number of
other cell lines for comparison, such as B16 (melanoma, originating from
a C57BL/6 mouse; H-2b), EL-4 (lymphoma/leukemia, from a C57BL/6
mouse; H-2b), L1210 (leukemia, from a DBA/2 mouse; H-2d), and
A431 (human epidermoid carcinoma) from laboratory stocks.
Cell preparation Suspensions of spleen cells and peritoneal exudate
cells (PEC) were prepared from 6- to 8-wk-old mice as described
previously (Nakashima et al, 1982; Dai et al, 1994). For preparation of
PEC, 1.5 ml of 10% proteose-peptone was inoculated intraperitoneally
3±4 d prior to collection of PEC. Cell type compositions of PEC were
determined by ¯ow cytometry after staining the cells with ¯uorescence-
labeled monoclonal antibodies (PharMingen, San Diego, CA) speci®c to
Thy-1 (CD95) for T cells, B220 (CD45R) for B cells, CD11b for
macrophages, or Ly-6G (Gr-1) for granulocytes. For some experiments,
PEC were treated with an anti-Thy-1 cytotoxic antibody (Nakashima et
al, 1982) and a low-toxic rabbit complement (ICN Pharmaceuticals,
Aurora) for elimination of Thy-1-bearing T cells or were incubated on a
plastic dish for 2 h to eliminate plastic-adherent cells, according to the
techniques described previously (Nakashima et al, 1982). The former and
the latter treatments reduced the ratios of T cells and macrophages
measured by ¯ow cytometry to less than 2% and less than 3%,
respectively. For some other experiments, a T-cell-enriched fraction was
obtained by passing PEC through a nylon wool column according to the
technique described previously (Nakashima et al, 1982). The purity of
this fraction, measured by ¯ow cytometry after staining cells in the
fraction with ¯uorescence-labeled anti-Thy-1 monoclonal antibody, was
86%±89%.
Assay of antitumor immunity PEC-mediated antitumor immunities
for tumor growth inhibition and tumor cell lysis were measured as
follows. For assays of immunity for tumor growth inhibition, we
prepared cultures containing Mel-Ret cells (2 3 104 cells per 200 ml per
well) plus or minus PEC (1±5 3 105) in 96-well plates for 2±3 d of
incubation. For some experiments, JTT (50±1600 mg per ml) was added
to the mixture of Mel-Ret cells and PEC at the time of starting the
culture. 3H-thymidine was added into the culture for the last 4 h of
incubation, and uptake of radioactivity into the cells was assayed as
described previously (Nagase et al, 1987).
The 51Cr-release test for measurement of tumor cell lysis was done as
described previously (Nagase et al, 1987). Brie¯y, Mel-Ret cells, which
were suspended in complete RPMI medium, were labeled with 51Cr by
incubating them in the presence of 0.1 mCi Na2
51CrO2 at 37°C for 1 h.
After washing four times with RPMI the 51Cr-labeled target cells
(1 3 104 cells per well) were mixed with effector cells (PEC) at different
E/T ratios in 200 ml of complete medium on 96-well plates and
incubated in the presence of 200 mg per ml of JTT for 18 h.
Radioactivity of 100 ml of culture supernatant was measured using an
Auto Well Gamma System-ARC370M (Aloka, Tokyo, Japan).
Maximum 51Cr release was measured by adding 0.2% Triton X-100, and
spontaneous release was measured by adding the medium only.
Cytotoxicity (%) was calculated using the following equation: cytotoxi-
city (%) = (experimental release ± spontaneous release)/(maximum
release ± spontaneous release) 3 100.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotting SDS-PAGE and immunoblotting
were performed as described elsewhere (Nakashima et al, 1991). In brief,
cells were lyzed by adding an equal volume of a 2-fold concentrated
sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 10% 2-
mercaptoethanol, 20% glycerol), and proteins thus obtained were
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subjected to SDS-PAGE on 8% gel. The proteins were then transferred
to a polyvinylidenedi¯uoride membrane. Subsequently, the membrane
was stained with an antipoly (ADP-ribose) polymerase (PARP) antibody
(Upstate Biotechnology, Lake Placid, NY) followed by goat antirabbit
IgG to horseradish peroxidase (Tago, Burlingame, CA). The protein
bands were visualized by Western Blot Chemiluminescence reagent
(DuPont NEN, Boston, MA) as directed by the manufacturer. The
molecular sizes of the developed proteins were determined by
comparison with prestained protein markers (New England Biolabs,
Beverly, MA).
RESULTS
JTT suppresses growth of melanocytic tumors that
spontaneously develop in RET-transgenic mice
Melanocytic tumors initially developed at about 21
2
mo after birth
in all mice in both JTT-treated (n = 35) and untreated control
(n = 35) groups, and there was no difference between the lengths
of the tumor-free stages in JTT-treated (74.6 6 29.0) and
untreated control (79.6 6 34.7) transgenic mice. All of the
tumors that developed in JTT-treated and untreated control
transgenic mice were melanocytic and appeared on the skin and/
or eyes (one to three tumors developed per mouse, one of which
usually became bigger than the other) invariably between the two
groups. As shown in Fig 1, however, the rates of tumor growth,
assessed by measurements of tumor volumes, were remarkably
reduced in the JTT-treated mice during the entire period after the
initial tumor development, compared with those in nontreated
littermate mice. Correspondingly, the life span of the JTT-treated
mice (509 6 182 d) was signi®cantly longer (> 6 mo in mean
value) than that of the untreated control mice (315 6 127 d), as
shown in Fig 2. Despite such obvious therapeutic effects of oral
administration of JTT on growth rates of tumors, the histology of
tumors at the terminal stage immediately before tumor death of the
JTT-treated mice was unchanged (data not shown) from that of
untreated control mice reported previously (Kato et al, 1998b).
JTT is not directly cytotoxic for growth inhibition to Mel-
Ret cells but promotes T cell activation In order to try to
determine the mechanism by which JTT suppresses tumor growth
for prolongation of the life span in vivo, we ®rst examined whether
JTT has direct cytotoxic action on a melanoma cell line (Mel-Ret
cells) in vitro compared with the action of SST, which was
previously shown to be cytotoxic (Kato et al, 1998b). As shown in
Fig 3, whereas 400 mg per ml of SST suppressed the growth of
Mel-Ret cells during 3 d of culture, none of a wide range of
concentrations (50±1600 mg per ml) of JTT showed this activity.
This result suggests that, unlike SST, JTT does not suppress tumor
growth through direct cytotoxic action on tumor cells. We next
measured the effect of the addition of various concentrations of
JTT into a culture of murine spleen cells on their growth in vitro. It
was shown in this experiment that 50±400 mg per ml of JTT acted
to promote DNA synthesis of cultured spleen cells, with a peak
level in the culture to which 200 mg per ml of JTT had been added
(Fig 4). These results suggested that JTT has an activity to
nonspeci®cally upregulate the host-immune mechanism, partially
agreeing with the results of earlier studies using other experimental
systems (Kiyohara et al, 1991).
JTT promotes speci®c antitumor T cell immunity As anti-
T-cell immunity was previously shown to develop in RET-
transgenic mice (Dai et al, 1994; Ichihara et al, 1995; Kato et al,
1999), we examined whether orally administered JTT promotes
generation of antitumor T cell immunity. We prepared PEC from
JTT-treated RET-transgenic mice and control untreated mice, and
we made cocultures with Mel-Ret cells for examination of the level
of tumor growth. As shown in Fig 5(A), the levels of 3H-
thymidine uptake in cultures of tumor cells mixed with 1 3 105/
Figure 1. Oral administration of JTT suppressed growth of
melanocytic tumors primarily developed in RET-transgenic
mice. Littermate RET-transgenic mice were divided into two groups,
one of which was given JTT by oral administration as described in
Materials and Methods. The volumes of tumors that developed on the skin
and/or eyes were measured (the size of the biggest tumor in each mouse
was measured) in JTT-treated (n = 35) and untreated control (n = 35)
transgenic mice. Tumor volumes in mice that died before 18 mo were
calculated as a continuation of the volume up to 18 mo. Values of means
6 SDs (vertical lines) are shown. *Signi®cantly different (*p < 0.001)
from the untreated control by the Mann±Whitney U test.
Figure 2. JTT prolonged the life span of RET-transgenic mice.
Survival rates of JTT-treated (a, n = 35) and untreated control (b, n =
35) transgenic mice were measured as described in the legend to Fig 1.
*,³Signi®cantly different (*p < 0.001; ³p < 0.05) from the untreated
control by the Mann±Whitney U test.
Figure 3. SST but not JTT directly inhibited the growth of Mel-
Ret cells in vitro. The indicated concentrations of SST or JTT were
added into the culture of Mel-Ret cells, and the culture was incubated
for 3 d for measurement of 3H-thymidine uptake. The experiment was
repeated three times, and basically the same results were obtained.
Representative data are presented. *Signi®cantly (*p < 0.001) different
from the control.
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5 3 105 PEC from JTT-treated mice were signi®cantly (p < 0.05/
p < 0.01) lower than those in cultures mixed with the same number
of PEC from untreated control mice. The former value might even
be overestimated for the growth of tumor cells because it could
have included uptake by potentially activated PEC. These results
suggest that there was an increase in antitumor immunity for tumor
growth inhibition in PEC from the JTT-treated transgenic mice.
More importantly, the addition of 200 mg per ml of JTT into a
mixed culture of Mel-Ret cells and PEC from JTT-treated RET-
transgenic mice at the start of the culture further promoted the
antitumor activity of the PEC from JTT-treated mice in vitro
(Fig 5B). When the antitumor-immunity-promoting effects of a
wide range of concentrations (50±1600 mg per ml) of JTT added
in vitro were examined, 200±400 mg per ml of JTT was shown to be
highly effective (data not shown). In this experimental protocol,
however, it was dif®cult to exactly measure the tumor-mediated
3H-thymidine uptake separately from the activated-PEC-mediated
uptake.
We therefore conducted experiments to directly measure
antitumor activity of PEC to kill tumor cells in vitro by the standard
51Cr-release test. As shown in Fig 6(A), PEC from JTT-treated
mice, but not those from nontreated control mice, displayed clear
cytotoxicity (up to > 20% 51Cr release/target cell killing) against
Mel-RET cells at E/T ratios of 10±90. The addition of 200 mM JTT
into the mixture of PEC and tumor cells further intensi®ed the
antitumor cytotoxicity (up to > 30%) of PEC from the JTT-treated
mice but did not change the cytotoxicity (around 10% or less) of
PEC from control mice (Fig 6B). These results, together with the
results presented in Fig 5, con®rmed that antitumor cytotoxic
immunity was increased in the PEC from JTT-treated mice.
We analyzed cell type composition of PEC by ¯ow cytometry.
The mean ratios of T cells, B cells, macrophages, and neutrophils in
PEC from untreated control mice were 10.4%, 15.3%, 61.8%, and
15.3% (n = 4), respectively, and those in PEC from JTT-treated
mice were 45.1%, 10.7%, 25.3%, and 20.3% (n = 4), respectively.
The increase in the ratio of T cells and the decrease in that of
macrophages in the latter PEC, compared with those in the former
PEC, were statistically signi®cant (p < 0.001/p < 0.005).
Moreover, the total number of PEC recovered from JTT-treated
mice (1.1 3 107 cells per mouse as the mean of six mice) was
signi®cantly (p < 0.05) larger than that of PEC from nontreated
control mice (3.4 3 106 cells per mouse). This indicated that the
number of T cells in the peritoneal cavity is increased in JTT-
treated mice.
Figure 5. PEC from the JTT-treated RET-transgenic mice displayed antitumor immunity to suppress the growth of Mel-Ret cells
in vitro. (A) Littermate RET-transgenic mice were divided into two groups, one of which was given JTT by oral administration for 2 wk. We
prepared mixed cultures of 2 3 104 Mel-Ret cells and indicated numbers of PEC from the JTT-treated or untreated control mice and incubated the
cultures for 3 d for measurement of 3H-thymidine uptake. Values of means 6 SDs of nine (3 3 3) cultures from three mice per group are presented.
The mean values in the cultures in which Mel-Ret cells alone were incubated were 3741 3 88. The experiment was repeated four times, and basically
the same results were obtained. Representative data are presented. *,²Signi®cantly different (*p < 0.001; ²p < 0.01) from the control. (B) We prepared
mixed cultures of Mel-Ret cells and PEC (5 3 105) from the JTT-treated or untreated control mice as in (A) with ( ) or without ( ) addition of
200 mg per ml of JTT and incubated the cultures for 3 d for measurement of 3H-thymidine uptake. Values of means 6 SDs of triplicate cultures are
presented. The experiment was repeated four times, and basically the same results were obtained. Representative data are presented. *Signi®cantly
different (*p < 0.001) from the control.
Figure 4. JTT stimulated murine spleen cells for DNA synthesis.
The indicated concentrations of JTT were added to cultures of murine
spleen cells, and the cultures were incubated for 3 d for measurement of
3H-thymidine uptake. Values of means 6 SDs of triplicate cultures are
presented. The experiment was repeated four times, and basically the
same results were obtained. Representative data are presented.
*,**,³Signi®cantly different (*p < 0.001, **p < 0.02, ³p < 0.05) from
the control.
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We next examined what cell type(s) conveyed the antitumor
cytotoxic immunity that was associated with PEC from the JTT-
treated mice. When we eliminated T cells from the PEC by
treatment with a cytotoxic anti-Thy-1 antibody and low-toxic
complement, the antitumor cytotoxicity of the PEC was totally lost
(Fig 7), con®rming the involvement of T cells as an essential
element in the antitumor cytotoxicity. Depletion of adherent cells
from PEC only partially decreased the level of antitumor
cytotoxicity. These results suggested that the major part of the
antitumor cytotoxicity is conveyed by cytotoxic T cells, although
some cytotoxicity may be carried by plastic-adherent macrophages
that are activated by antitumor T cells.
The antitumor cytotoxicity was further examined with the
fraction of PEC that was enriched in T cells. As shown in Fig 8,
the T-cell-enriched fraction of PEC from JTT-treated mice, which
had been incubated with Mel-Ret cells in the presence of
additional JTT in vitro, displayed high cytotoxicity (up to > 40%)
against Mel-Ret cells at E/T ratios of 2±20. This level of
cytotoxicity was signi®cantly higher than the level of background
cytotoxicity of the T-cell-enriched fraction of PEC from control
mice. This ®nding proved that T-cell-dependent antitumor
cytotoxic immunity was induced in PEC by oral administration
of JTT to RET-transgenic mice.
Antigen speci®city of the PEC-associated antitumor cytotoxic
immunity was then examined. We prepared mixed cultures of each
of ®ve different cell lines (Mel-Ret, B16, EL-4, A431, and L1210)
and PEC from JTT-treated or untreated mice, with addition of
JTT in the culture. As shown in Fig 9, PEC from the JTT-treated
transgenic mice, which displayed strong cytotoxicity against MHC-
compatible Mel-Ret, showed signi®cant but weaker cytotoxicity
against another MHC-compatible melanoma cell line, B16, but
barely showed cytotoxicity against any of the third-party MHC-
compatible lymphoma EL-4 cells, MHC-incompatible leukemia
L1210 cells, and human epidermoid carcinoma A431 cells. These
results revealed that the immunity was basically Mel-Ret-speci®c
with cross-reactivity to another MHC-compatible melanoma cell
line, B16. It was concluded from all of these results that the
cytotoxic immunity that developed in the peritoneal cavity of JTT-
treated mice is principally conveyed by tumor antigen (RET/
melanoma) speci®c cytotoxic T cells.
In order to partially identify the mechanism of antitumor
cytotoxic immunity displayed by PEC from JTT-treated mice, we
tested the ability of PEC after 3 d of incubation with Mel-Ret cells
in vitro to induce caspase activation for degrading PARP as a
substrate of caspase-3 in fresh Mel-Ret cells. As shown in Fig 10,
the density of the band of intact PARP, which was high in the lane
for Mel-Ret cells in the control culture (lane 1), decreased,
accompanying an increase in the density of the band of degraded
PARP, in the lane for Mel-Ret cells cultured together with PEC
from JTT-treated mice (lane 2). Such PARP degradation did not
occur on incubating tumor cells with PEC from control mice
(lane 4). This activity of PEC from JTT-treated mice was abolished
by previously eliminating T cells from PEC before cultivation
(lane 3). These results suggest that the PEC-mediated T-cell-
dependent antitumor immunity involves induction of apoptotic
death of Mel-Ret cells.
Partial identi®cation of ingredients of JTT that are
responsible for enhancing the PEC-associated antitumor
cytotoxic immunity We ®nally tested the actions of each of
several known major ingredients of JTT, including glycyrrhizin,
paeoni¯orin, gensenoside Rb1, and liquiritin, on the antitumor
cytotoxic immunity of PEC from the JTT-treated transgenic mice.
The results are shown in Fig 11. Amongst the four major
ingredients of JTT tested, only glycchirrizin signi®cantly
augmented the antitumor cytotoxicity of PEC when added
in vitro, although its effect was weaker than that of the original
JTT. This result suggests that glycyrrhizin is involved in the active
component of JTT, although another undetermined ingredient(s)
in JTT, possibly in cooperation with glychrrizin, is needed for
complete action.
DISCUSSION
In this study, we demonstrated that daily oral administration of JTT
from 4 wk after birth suppressed the growth of melanocytic tumors
that spontaneously developed in RET-transgenic mice. This is the
®rst report describing a clear antitumor effect of the herbal
medicine JTT on primarily developed tumors and on malignant
melanoma in an animal model. Our results encourage a future
evidence-based usage of this herbal medicine in clinics for
controlling malignant melanoma in humans. More interestingly,
there were clear differences between the mode of suppression of
tumor growth by JTT and that of the previously reported tumor
growth inhibition by SST (Kato et al, 1998a) in the same animal
model. First, SST (Kato et al, 1998) but not JTT (this study)
prolonged the tumor-free stage. Second, JTT suppressed tumor
growth during the entire period after the tumor had initially
developed, whereas SST worked preferentially in the early and
middle stages but had almost no effect in the late stage.
Consequently, the life span of the JTT-treated transgenic mice
(> 6 mo prolongation in mean value) was more extensively
prolonged than was that of SST-treated mice (2.7 mo prolonga-
tion). This difference has been shown to be connected to distinct
action mechanisms of the two herbal medicines.
Regarding the mechanism by which JTT inhibits tumor growth,
we showed that, unlike SST, which was directly cytotoxic to tumor
cells in vitro (Kato et al, 1998a; Liu et al, 1998), JTT displayed no
demonstrable direct cytotoxicity against tumor cells in vitro, at any
of the wide range of concentrations tested in this study. This might
be mainly because JTT does not contain bicalin, which is the major
cytotoxic ingredient of SST. The addition of JTT to a culture of
murine spleen cells promoted their DNA synthesis. This result
basically corresponds to earlier reports that JTT acts to stimulate T
cell activities (Kiyohara et al, 1991). The most striking result in our
Figure 6. PEC from the JTT-treated RET-
transgenic mice displayed antitumor
cytotoxic immunity in vitro. PEC were
prepared from JTT-treated and untreated control
mice as described in the legend of Fig 5.
Cytotoxicity of these PEC was measured by
the51Cr-release test by incubating 51Cr-labeled
target cells with different numbers of effector PEC
at indicated E/T ratios in the presence (B) or
absence (A) of additional (200 mg per ml) JTT
according to the method described in Materials and
Methods. *,³Signi®cantly different (*p < 0.001; ³p
< 0.05) from the control.
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study was that PEC from the JTT-treated RET-transgenic mice
displayed a clear antitumor cytotoxicity against Mel-Ret cells
in vitro, and this antitumor activity was further augmented by the
addition of JTT into the culture. The antitumor cytotoxic
immunity that had been primarily developed in JTT-treated mice
and had been ampli®ed by JTT added in vitro in the presence of
Mel-Ret cells bearing tumor antigens was shown to be fully Thy-
1-bearing T-cell-dependent. Moreover, the immunity speci®cally
targeted Mel-Ret cells and, in part, MHC-compatible B16
melanoma cells, but not third-party MHC-compatible EL-4
lymphoma cells, MHC-incompatible L1210 leukemia cells, or
human A431 epidermoid carcinoma cells. We previously revealed
that RET antigen or RET-induced tumor-speci®c antigen(s)
worked as a tumor transplantation antigen to induce both cytotoxic
T cell immunity and T cell/macrophage-mediated immunity when
alloantigen-containing RET-antigen-bearing tumor cells or re-
combinant RET antigen were inoculated into RET-transgenic
mice (Dai et al, 1994; Ichihara et al, 1995) or into a line of RET-
transgenic mice that were not neonatally tolerant to the RET
antigen (Kato et al, 2000). In this study, we showed that immune
peritoneal T cells attacked Mel-Ret cells, resulting in growth
inhibition and cell death, partially involving the action of plastic-
adherent cells. Additional experiments revealed that the rate and
number of T cells were increased in the peritoneal cavity of the
JTT-treated RET-transgenic mice and that nylon-wool-puri®ed T
cells from PEC of the JTT-treated mice displayed high cytotoxicity
against Mel-Ret cells. Evidence that the JTT-promoted antitumor
cytotoxic immunity involves activation of caspases in the target
tumor cells was also obtained. Taken together, our results suggest
that JTT assisted T cells in becoming effectively sensitized to RET
and potentially RET-induced melanoma-common antigens for
Figure 7. PEC-associated antitumor cytotoxic immunity is T-
cell-dependent. We prepared PEC from the JTT-treated and untreated
control mice. Portions of these PEC were treated with a cytotoxic anti-
Thy-1 antibody and low-toxic complement (T-cell-depleted) or were
depleted of adherent cells (AD-cell-depleted). We prepared mixed
cultures of Mel-Ret cells and original PEC, T-cell-depleted PEC, or
AD-cell-depleted PEC from the JTT-treated ( ) or control ( ) mice (E/
T ratio = 90), in the presence of 200 mg per ml of JTT, for
measurement of 51Cr release. Although not shown in the ®gure,
treatment of PEC with a low-toxic complement alone did not detectably
decrease the cytotoxicity. Values of means 6 SDs of triplicate cultures
are presented. The experiment was repeated four times, and basically the
same results were obtained. Representative data are demonstrated.
*Signi®cantly different (*p < 0.001) from the control.
Figure 8. Nylon-wool-puri®ed T cells display antitumor cytotoxic
immunity. A T-cell-enriched fraction was prepared from PEC that had
been obtained from JTT-treated and untreated control mice. We
prepared mixed cultures of Mel-Ret cells and nylon-wool-puri®ed T
cells from the JTT-treated (j) or control (h) mice (E/T ratio = 90), in
the presence of 200 mg per ml of JTT for measurement of 51Cr release.
Values of means 6 SDs of triplicate cultures are presented. *Signi®cantly
different (*p < 0.001) from the control.
Figure 9. Speci®city of PEC-associated antitumor cytotoxic
immunity. We prepared mixed cultures of PEC from JTT-treated ( )
or untreated control ( ) mice and one of various tumor cell lines such as
Mel-Ret, B16, EL-4, L1210, and A431 (E/T ratio = 90) in the presence
of 200 mg per ml of JTT for measurement of 51Cr release. Values of
means 6 SDs of triplicate cultures are presented. The experiment was
repeated three times, and basically the same results were obtained.
Representative data are presented. *,³Signi®cantly different (*p < 0.001;
³p < 0.02.) from the control.
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generating mainly cytotoxic T cell immunity and partially T cell/
macrophage-mediated immunity. Isolation of a tumor-speci®c
cytotoxic T cell clone(s) for potential adoptive immune therapy for
primarily developed melanoma is in progress as the second step of
this series of studies.
JTT is composed of extracts from 10 herbs and contains various
chemicals, including liquiritin, glycyrrhizin, paeni¯orin, and
ginsenoside, as the major ever-known ingredients. These chemicals
may together have a complex effect on the immune response to
tumor antigens. We showed that, amongst the several chemical
ingredients examined, glycyrrhizin could replace in part the action
of JTT on promotion of the antitumor immunity of PEC to
suppress tumor growth in vitro. The exact mechanism by which
glycyrrhizin acts remains to be clari®ed. We previously showed,
however, that glycyrrhizin displays a number of actions to
upregulate T cell responses to anti-CD3 antibody or Con A for
DNA synthesis and cytokine production through modi®cation of
intracellular signal transduction (Zhang et al, 1992, 1993, 1995).
Glycyrrhizin was also shown to modulate MHC class I antigen
expression on various cells (Zhang et al, 1990) and NO synthesis by
macrophages (Yi et al, 1996). Some or all of these effects of
glycyrhizin were probably responsible for the glycyrrhizin-medi-
ated augmentation of the PEC-associated antitumor immunity, and
other undetermined elements of JTT might have worked in
synergy with glycyrrhizin for the in vivo and in vitro effects. The
demonstrated mechanism of JTT antitumor action, however, is
probably one of the many complex ones mediated by each of a
number of ingredients of JTT in combination.
It is noted that two herbal medicines, JTT (this paper) and SST
(Kato et al, 1998a), showed very different antitumor effects in the
same animal model. Alhough a number of ingredients, including
glycirrhizin, are contained in the two medicines (although the
quantities are different ± JTT contains more glycirrhizin than SST,
for example), bicalin, which is one of the major components of SST
and is cytotoxic to tumor cells (Kato et al, 1998), is not included in
JTT. This suggests that a herbal medicine such as SST that displays
direct cytotoxicity-based antitumor activity eliminates tumors most
effectively in the early stage of tumor development, when the
tumor is small, but has little effect in the late stage, when the tumor
has become large. In contrast, a herbal medicine like JTT showing
T-cell-immunity-based antitumor activity acts effectively after the
tumor has developed to a size that is capable of stimulating T cell
immunity. An appropriate stage-oriented combination of the two
herbal medicines, using SST in the early stage and JTT in the later
stage, for example, may provide a good therapeutic protocol.
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Research Foundation for Oriental Medicine.
Figure 10. Activated T cells that developed in a 3 d culture of
Mel-Ret cells and PEC from the JTT-treated transgenic mice
induced caspase activation in fresh Mel-Ret cells. We prepared
mixed cultures of Mel-Ret cells (2 3 104) and PEC (1 3 105) from
JTT-treated or nontreated control transgenic mice (see the legend of
Fig 5) and incubated the cultures for 3 d in the presence of 200 mg per
ml of JTT. Fresh Mel-Ret cells (1 3 105) were then incubated for 2 d
in the cultures containing fresh medium with (lanes 2±5) or without (lane
1: control) PEC from JTT-treated (lanes 2 and 3) or nontreated control
(lanes 4 and 5) mice that had been incubated in the ®rst-step 3 d culture.
For lanes 3 and 5, T cells were eliminated by previously treating PEC
with an anti-Thy-1 and complement before the start of the ®rst culture.
Cells collected after the second culture were lyzed by sample buffer and
subjected to SDS-PAGE followed by immunoblotting with anti-PARP
antibody. Positions of undegraded (116 kDa) and degraded (85 kDa)
PARP molecules are shown on the right. The experiment was repeated
four times and basically the same results were obtained. Representative
data are presented.
Figure 11. PEC-associated antitumor-cytotoxic-immunity-pro-
moting activities of ingredients of JTT. We prepared mixed cultures
of PEC from the JTT-treated mice and Mel-Ret cells (E/T ratio = 90) in
the presence ( ) or absence (j) of each of the indicated ingredients at the
concentrations contained in 200 mg per ml of JTT for measurement of
51Cr release. Values of means 6 SDs of triplicate cultures are presented.
The experiment was repeated three times, and basically the same results
were obtained. Representative data are presented. ²,³Signi®cantly
different (²p < 0.01; ³p < 0.05) from the control.
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